Spinal cord atrophy in people with diabetic neuropathy Nervous System Diseases Spinal cord atrophy in people with diabetic neuropathy
Conditions
Interventions
There will be 5 study groups:
1. Diabetes without diabetic peripheral neuropathy (DM-DPN)
2. Diabetes with diabetic peripheral neuropathy (DM+DPN)
3. He
Sponsors
University of Nottingham
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 75 years 2. Able to give informed consent 3. Able to speak and understand English language 4. Diagnosis consistent with one of the study groups (diabetes without diabetic peripheral neuropathy, diabetes with diabetic peripheral neuropathy, healthy volunteers, multiple sclerosis, or other peripheral neuropathies) with initial symptoms having preceded inclusion into the study by 12 months and/or condition stable for =2 months
Exclusion criteria
Exclusion criteria: 1. Extensive cardiovascular and/or cerebrovascular comorbidity (treatment for angina or peripheral vascular disease constitutes a contraindication) 2. Other comorbidities, in particular neurological diseases, that in view of the researcher may interfere with the study 3. Significant spinal or spinal cord disease (other than MS in the MS control group) 4. Contraindications for MRI including but not restricted to pacemaker, orbital foreign body, certain aneurysm clips, claustrophobia, and un-removable piercings 5. Pregnancy or planning for pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Upper cervical cord area measured using magnetic resonance imaging at baseline and between 12 and 24 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Lower cervical cord area measured using magnetic resonance imaging at baseline and between 12 and 24 months 2. Mid-thoracic cord area measured using magnetic resonance imaging at baseline and between 12 and 24 months 3. Brain volume measured using magnetic resonance imaging at baseline and between 12 and 24 months 4. Clinical severity of diabetic neuropathy measured using clinical examination, vibration perception threshold, and neuropathic pain scores at baseline and between 12 and 24 months | — |
Countries
England, United Kingdom
Outcome results
None listed